Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05252754 · ClinicalTrials.gov registry record · Phase 3
Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis
A Phase 3 study of Post-ERCP Acute Pancreatitis, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 4,874
- Enrollment target
- 5
- Study locations
NCT05252754 is a Phase 3 study of Post-ERCP Acute Pancreatitis that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 4,874 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT05252754, a Phase 3 study of Post-ERCP Acute Pancreatitis, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 4,874 participants
- Enrollment target
- 5
- Study locations
Study Summary
This research is being done to see if using oral tacrolimus before endoscopy, can prevent pancreatitis that may occur after ERCP (a type of gastrointestinal endoscopy).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tacrolimus capsule
- DRUG Rectal Indomethacin
Study Locations (5)
Other
- Post Graduate Institute of Medical Education and Research - Chandigarh
- Singapore General Hospital - Singapore
Maryland
- Johns Hopkins Hospital - Baltimore
Andhra Pradesh
- Asian Institute of Gastroenterology - Hyderabad
West Bengal
- Apollo Multispecialty Hospitals, - Kolkata
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,874 participants |
| Start Date | 2023-01-18 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05252754
The ClinicalTrials.gov registry entry for NCT05252754 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 4,874 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Post-ERCP Acute Pancreatitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05252754 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Other, Maryland, Andhra Pradesh.
Frequently Asked Questions
What is clinical trial NCT05252754 about?
NCT05252754 is a clinical study titled "Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis". This research is being done to see if using oral tacrolimus before endoscopy, can prevent pancreatitis that may occur after ERCP (a type of gastrointestinal endoscopy).
What is the current status of trial NCT05252754?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 4,874 participants. The study started on 2023-01-18. Estimated completion is 2026-12.
What conditions does trial NCT05252754 study?
This clinical trial studies the following conditions: Post-ERCP Acute Pancreatitis.
What interventions are being tested in trial NCT05252754?
The interventions under investigation include: Placebo (DRUG), Tacrolimus capsule (DRUG), Rectal Indomethacin (DRUG).
Who is sponsoring clinical trial NCT05252754?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05252754 being conducted?
This trial has 5 study locations across Maryland, Andhra Pradesh, West Bengal. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post-ERCP Acute Pancreatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.